Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has ...
- Agreement provides additional funding tool of up to $25 million over a period of up to 36 months - Underpins the Company’s ambitions to expand its commercialisation activities and advance its ...
DUBLIN, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable ...
DUBLIN, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable ...
Clinical trial results support progression of CGM+ toward regulatory submissions and scaled commercialization - Anticipating initiation of pivotal clinical trial in 2026 - Updated electronics ...
Trinity Biotech plc (NASDAQ: TRIB) stock surged Tuesday after the diagnostics company announced a pair of developments that significantly altered its near- and long-term outlook. Investors reacted ...
Trinity Biotech plc announced that it has achieved Adjusted EBITDA-positive operations during Q2 2025 and expects to maintain this positive trajectory going forward, marking a key milestone in its ...
The MarketWatch News Department was not involved in the creation of this content. - TrinScreen HIV order signals renewed strength in global HIV testing market - Company also reports a key milestone of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results